

VeCollal Type II vs. UCII

Clinical Efficacy Evaluation

E.V.E. LAB

2024.07.31



Human Trial – VeCollal II vs. UCII

Preface: The aim of the study is to evaluate the efficacy of VeCollal II and UCII on joint health.

❑ Test sample:

- ① VeCollal II sachet: 1.7 g/day
- ② UCII sachet: 40 mg/day

❑ Subjects: Total 12 participants, VeCollal II : UCII = 7 : 5

❑ Inclusion criteria:

- ① Above 18 years old
- ② Pain score of WOMAC above 2.0 or total score of WOMAC above 12, without the use of joint treatment-related medication

❑ Test method: A randomized, single-blind, parallel study was conducted. Take 1 sachet of the test sample daily for 8 consecutive weeks. Fasting blood and WOMAC questionnaire were collected on week 0, week 4, and week 8.

❑ Test item:

- ① Self-assessment questionnaire: WOMAC
- ② Blood- inflammatory indicators: hs-CRP, TNF- α , dickkopf factor 1 (DKK-1)



Human trial


VeCollal II vs. UCII _ Overall osteoarthritis condition

The severity of osteoarthritis in participants was assessed using the WOMAC questionnaire, where higher scores indicate more severe joint discomfort. After 8 weeks of continuous use, the UCII group showed a reduction of 5.8 points (-22.9%) in WOMAC total scores, and the VeCollal II group showed a reduction of 6.2 points (-28.1%).

WOMAC Osteoarthritis index, which assess the severity of arthritis based on the symptoms and signs of patients. This index evaluates three aspects: pain, stiffness, and difficulty in physical mobility. Each question is scored on a scale of 0-4. **The higher the score on the WOMAC, the more severe the arthritis discomfort is.**

Inclusion criteria : Pain score of WOMAC above 2.0 or total score of WOMAC above 12.

WOMAC total score




Human trial

VeCollal II vs. UCII _ Osteoarthritis symptoms

After 8 weeks of continuous use, the WOMAC results for joint pain, stiffness, and mobility showed:

Both UCII and VeCollal II can relieve joint pain, stiffness and joint mobility.

VeCollal II is better than UCII in improving joint stiffness and mobility.



DEVELOPING A VISION FOR YOUR FUTURE.

Join & Delight

